SB 202190

Grouped product items
SizePrice Qty
10mg
$30.00
25mg
$55.00
Catalog Number : 1523072

description

SB 202190 is a selective and potent p38 MAP kinases inhibitor, binding to its ATP pocket. It has negligible inhibiting properties on other MAP kinases such as ERKs and JNKs. SB 202190 is reported to be used to induce cardiomyocyte differentiation from human embryonic stem cells and increase neural stem cell self-renewal.
product image

Additional Information

Applications:
FA
Synonyms:
SB-202190, SB202190, FHPI, 4-[4-(4-Fluorphenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol
Formulation:
Crystalline solid
Chemical Name:
4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one
Molecular Formula:

C20H14FN3O

Molecular Weight:
331.3
CAS Number
152121-30-7
Purity:
≥98%
Storage Conditions:
Product should be kept at -20°C.
References:

Nemoto, S., Xiang, J., Huang, S., & Lin, A. (1998). Induction of apoptosis by SB202190 through inhibition of p38β mitogen-activated protein kinase. Journal of Biological Chemistry273(26), 16415-16420.

Manthey, C. L., Wang, S. W., Kinney, S. D., & Yao, Z. (1998). SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. Journal of leukocyte biology,64(3), 409-417.

Hirosawa, M., Nakahara, M., Otosaka, R., Imoto, A., Okazaki, T., & Takahashi, S. (2009). The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. Leukemia research,33(5), 693-699.

© BioGems International, Inc. All rights reserved.